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Purpose: To explore the contribution of flow cytometry
immunophenotyping (FCI) in detecting leptomeningeal
disease in patients with solid tumors.
Experimental design: Cerebrospinal fluid (CSF) samples
from 78 patients who received a diagnosis of epithelial-cell
solid tumors and had clinical data suggestive of leptome-
ningeal carcinomatosis (LC) were studied. A novel FCI
protocol was used to identify cells expressing the epithelial
cell antigen EpCAM and their DNA content.
Accompanying inflammatory cells were also described.
FCI results (positive or negative formalignancy) were com-
paredwith those fromCSF cytology andwith the diagnosis
established by the clinicians: patients with LC (n¼ 49),
without LC (n¼ 26), and undetermined (n ¼ 3).
Results: FCI described awide range of EpCAM-positive
cells with a hyperdiploid DNA content in the CSF of
patients with LC. Compared with cytology, FCI showed
higher sensitivity (75.5 vs 65.3) and negative predictive
value (67.6 vs 60.5), and similar specificity (96.1 vs 100)
and positive predictive value (97.4 vs 100). Concordance
between cytology and FCI was high (Kp¼ 0.83), although
misdiagnosis of LC did not show differences between eval-
uating the CSF with 1 or 2 techniques (P¼ .06). Receiver-
operator characteristic curve analyses showed that lym-
phocytes and monocytes had a different distribution
between patients with and without LC.
Conclusion: FCI seems to be a promising new tool for
improving the diagnostic examination of patients with
suspicion of LC. Detection of epithelial cells with a
higher DNA content is highly specific of LC, but evalu-
ation of the nonepithelial cell compartment of the CSF
might also be useful for supporting this diagnosis.
Keywords: flow cytometry, immunophenotype,
leptomeningeal carcinomatosis.
L
eptomeningeal carcinomatosis (LC) is a devastat-
ing cancer complication developing in at least
5%–10% of patients with solid tumors. Its prog-
nosis is poor, with a median survival of 3–6 months
among patients receiving chemotherapy.1–3 Early diag-
nosis of LC and treatment initiation could offer the best
chance of controlling symptoms and prevent the estab-
lishment of irreversible neurologic deficits that impair
the patient’s quality of life.3–5 However, LC diagnosis
currently remains a challenge. Cytological identification
of malignant cells in the cerebrospinal fluid (CSF)
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remains the gold standard for LC diagnosis, but up to 45%
of patients have an initial negative result of cytological
examination of the CSF. This sensitivity may increase up
to 90% when a high number of lumbar punctures are per-
formed.6,7 The implementation of imaging techniques and
biochemical analysis of the CSF offers useful information
for diagnosis; however, both of them should be considered
in the right clinical context, because they lack specificity
and their sensitivity is low.1,3 It is therefore imperative to
improve diagnostic tools.
Multiparametric flow cytometry immunophenoty-
ping (FCI) is an established and necessary laboratory
instrument for diagnosis and follow-up of a wide range
of hematological malignancies. In turn, FCI is not routi-
nely used for the study of nonhematological tumors.
Today, the number of monoclonal antibodies (mAbs)
directed against nonhematopoietic antigens is progress-
ively increasing, and authors have recently shown the
potential role of FCI in distinguishing mesothelioma
and adenocarcinoma,8 identifying epithelial neoplasms
in body fluids9 and detecting micrometastases in sentinel
lymph node.10,11 In all these situations, the main advan-
tage of FCI over cytology is a rapid and early diagnosis in
relatively urgent clinical situations.8,9,12
The aim of this prospective study was to explore the
contribution of FCI to identify LC in a group of patients
with solid tumors and clinical data suggesting LC.
Previous studies on aggressive lymphoma13–15 showed
a better sensitivity of FCI over classical cytology examin-
ation of the CSF for the diagnosis of meningeal dissemi-
nation. To the best of our knowledge, this is the first time
that FCI was used to evaluate the CSF of patients with
solid tumors in search of LC.
Material and Methods
Clinical Data
From March 2009 through July 2010, 99 patients who
received a diagnosis of solid tumors were recruited for
the study in 28 Spanish hospitals. Inclusion criteria were
a previous diagnosis of epithelial-cell neoplasia and the
development of clinical signs or symptoms suggestive of
LC. Patients with no history of neoplasia but serious sus-
picion of LC were also considered. Those with hemato-
logical malignancies, melanoma, primary brain tumors,
or those receiving intrathecal treatment for LC before
sending a CSF sample for study were excluded.
A complete data collection and follow-up was per-
formed in 78 patients (median age, 57+12; 54
females) from 19 participating hospitals. The remaining
patients with incomplete submitted information were
excluded, and per protocol analyses were performed.
In 2 patients of the series, 2 neoplasms were simul-
taneously detected: breast and gastrointestinal adenocarci-
noma in the first patient, and colon and lung
adenocarcinoma in the second one. The primary location
of the tumor was unknown in 4 patients. In the remaining
72, the distribution of tumors was the following: breast
(n ¼ 44), lung (n ¼ 23), gastrointestinal (n ¼ 4), and
cavum (n ¼ 1). Adenocarcinoma was the histology
subtype in 69 patients, and the remaining were 1
oat-cell, 2 squamous cell lung carcinoma, 3 undifferen-
tiated tumors, 2 carcinomas with unknown primary
location, and 1 malignant radiological lung lesion
without histology. Clinical features, primary tumor-related
characteristics, and CSF findings were also registered.
Study Design
After neurological signs or symptoms appeared in a
patient with cancer or suspicion of cancer, a neuraxis
MRI was performed, and then a CSF sample was
obtained for cellular studies (FCI and cytology) and bio-
chemical tests (protein and glucose concentration; see
Fig. 1). The clinician at the institution of origin was
responsible for equally distributing the volume of CSF
obtained for cellular studies into 2 tubes: the one not con-
taining fixative agent was sent for cytology examination
and the one with fixative agent was sent for FCI studies.
FCI was blinded to cytology and MRI data.
Fig. 1.
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Definitive LC diagnosis for every patient studied was
verified by the clinicians at each hospital, based on either
detection of malignant cells in CSF, on radiological find-
ings consistent with LC on MRI, or biochemical
abnormalities in the CSF.4 MRI studies and the cytologi-
cal and biochemical examination of the CSF were done
at the institution of origin using validated standard pro-
tocols and machines. Basic guidelines for cytological
examination were dilution of CSF, location of an appro-
priate sample volume on a cytospin, and centrifugation.
Films were dried and stained (Papanicolau and/or
Giemsa) for light microscopy. No immunocytochemical
analyses were performed for epithelial adhesion mol-
ecule (EpCAM).
CSF glucose levels were measured using enzymatic
assays, and protein level measurements were performed
using either turbidimetric or colorimetric procedures.
FCI analyses were centralized at Fundacio´n Jime´nez
Dı´az (Madrid, Spain). FCI was only used as complemen-
tary information, and clinicians did not establish the
diagnosis of LC based only on FCI data.
Local ethics committees of participating institutions
approved the study, and informed consent was obtained
from each patient before enrolment. All procedures were
in accordance with the ethical standards of the Helsinki
Declaration.
Samples and FCI Studies
CSF samples obtained from a lumbar puncture (n ¼ 77)
and from an Ommaya reservoir (n ¼ 1) were collected in
EDTA tubes containing 0.2 mL of an immunofixative
reagent (Transfix, Immunostep SL), necessary to guaran-
tee safe transportation. Volume and macroscopic
characteristics (including blood contamination or not)
of each CSF sample were recorded. All samples were
processed within 5 days from extraction at the
Fundacio´n Jime´nez Dı´az in accordance with current
FCI recommendations for processing CSF samples in
search of hematological malignancies.16
An aliquot of the CSF sample received was used for
cell count using the fluorescent dye DRAQ5 (Biostatus
Limited) for DNA staining17,18 and Perfect-COUNT
microspheres (Cytognos). The remaining sample was
equally distributed into 2 different aliquots (tube 1 and
tube 2). After centrifugation, a 2-step procedure was
applied for the cell-pellet staining. Tube 1 was always
stained with a 2-color (fluorescein isothyocyanate,
FITC/phycoeritrin, PE) mAb combination directed
against the epithelial cell antigen molecule. Ber-EP4
FITC (clone Ber-EP4) was purchased from DAKO
Cytomation and EpCAM-PE (clone EBA-1) from BDB.
After incubation (30 min in the dark) and centrifu-
gation (5 min at 540 g), the cell pellet was resuspended
in PBS, and an appropriate dilution of DRAQ5 was
added. The whole volume of sample was acquired on a
FACSCantoII (Becton Dickinson Biosciences [BDB])
using the FACSDiva software (BDB). Analyses were per-
formed using the INFINICYT software program
(Cytognos). If the result of tube 1 was negative for
malignancy or not conclusive, the same combination of
mAb described for tube 1 was added to tube 2. If the
result was positive for malignancy, tube 2 was stained
with a 4–6-color mAb combination to confirm the epi-
thelial origin of the malignant cells (intracellular cyto-
keratin) and label the inflammatory cell populations.
FCI categorized a sample as positive for malignancy
when at least 10 clustered events were positive for the
2 mAbs directed against EpCAM. The sequence of FCI
analysis included identification of nucleated cells
through DRAQ5 staining and then localization of epi-
thelial cells using information from FITC and PE
signals (Fig. 2). Calculation of DNA index was per-
formed in those cases with sufficient number of events
corresponding to epithelial cells. Ploidy was expressed
as the ratio of the peak value of fluorescence intensity
of epithelial cells with respect to that of lymphocytes
(diploid cell compartment).19 Lymphocytes, monocytes,
and polimorphonuclear cells were located on the basis of
their forward and side scatter characteristics or infor-
mation obtained from additional mAb.
Statistics
First, we determined the usefulness of cytology and FCI
for diagnosing LC by calculating the sensitivity, speci-
ficity, and the positive and negative predictive values.
Correlation between the 2 diagnostic methods was per-
formed by k index with 95% confidence interval (CI),
and statistical difference between cytology and FCI
was assessed by McNemar test. Second, we focused on
the description of the FCI findings in every group ident-
ified by FCI, and the x2 was used to identify differences
among them. Quantitative variables were expressed as
median and interquartile range. Third, we considered
nonepithelial cells to determine whether they could
also be helpful in predicting LC. The nonparametric
tests used were Kruskal-Wallis test for multiple compari-
sons and Mann-Whitney test for comparisons between 2
groups. A 2-sided P value ,.05 was considered as a stat-
istically significant difference. Receiver-operator charac-
teristics (ROC) analysis was used to compare the
capability of the inflammatory subpopulations to dis-
criminate between cases with and without LC.
Calculations were performed using the SPSS software
package, version 12.0 (SPSS).
Results
Accuracy Between FCI Examination and Current LC
Diagnostic Criteria
LC was established in 49 of 78 patients. Supplementary
Table 1 shows the results of the diagnostic tests per-
formed on each patient. In brief (Table 1), CSF cytology
was the basis for diagnosing LC in 32 patients, and for
the remaining 17, diagnosis of LC required suitable clini-
cal symptoms and signs and either MRI and biochemical
CSF findings (n ¼ 11), MRI only (n ¼ 2), or only posi-
tive CSF biochemical data (n ¼ 4).
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FCI detected a wide range of EpCAM-positive cells
(0.1%–91%) in the CSF from patients with LC and
positive CSF cytology. FCI also identified malignant epi-
thelial cells in 5 additional cases in which CSF cytology
was negative for malignancy (Figure 3). In these patients
with negative cytology and positive FCI data (patients
45–49; Supplementary Table 1), the final diagnosis of
LC was established by MRI and CSF biochemical data
(n ¼ 4) or biochemical data alone (n ¼ 1) and was con-
firmed by clinical follow-up. Only one of these patients
had brain metastases. In turn, the remaining 12 cases
Fig. 2. Dot-plots showing an EpCAM positive CSF sample (A–F) and a negative sample for LC (G, H). Consecutive steps for data analysis:
first step (A): identification of the CSF cell compartment based on the selection of DRAQ5 positive events. Second step (B): single-cell gate
based on the selection of FSC-H vs FSC-A. Third step (C): identification of epithelial cells (ep) based on expression of EpCAM. Forth step
(D, E): confirmation of a higher DNA content on epithelial cells with respect to lymphocytes DNA content. Fifth step (F): identification of
inflammatory cells: lymphocytes (ly) and monocytes (mo). Epithelial cells (ep) have a heterogeneous size (FSC, forward scatter), and
granularity (SSC, side scatter) as compared to lymphocytes and monocytes. No positive cells for the mAb Ber-EP4 and EpCAM are found
in G and H. Positive staining for CD14 identifies monocytes. FITC: fluorescein isothiocyanate; PE: phycoerythrin.
Table 1. Description of methods used for diagnosis of LC
LC (n5 49)
Negative CSF
cytology
Positive CSF
biochemistry
Negative CSF
biochemistry
Positive MRI 11 2
Negative MRI 4 0
Positive CSF
cytology
32
Abbreviations: LC, leptomeningeal carcinomatosis; CSF,
cerebrospinal fluid; MRI, Magnetic resonance imaging.
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Fig. 3. FCI data from patients in the TP FCI group. Epithelial cells are painted in dark black, and inflammatory cells in grey. In all cases,
cytology was informed as no data of malignancy. Volume of CSF sample received, CSF cell-count and percentage of malignant cells
detected by FCI in every patient are specified. FSC: forward scatter; SSC: side scatter; FITC: fluorescein isothiocyanate; PE: phycoerythrin.
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with LC (5 lung and 7 breast adenocarcinoma) had
double negative CSF cytology and FCI findings (patients
33–44; Supplementary Table 1).
LC was excluded in 26 patients, and after 6 months
of follow-up, other diagnoses were determined in 23
of these 26 patients: B cell non-Hodgkin lymphoma
(n ¼ 1), infectious meningitis (n ¼ 2), myasthenia gravis
(n ¼ 1), amyotrophic lateral sclerosis (n ¼ 1), peripheral
vestibular syndrome (n ¼ 2), benign facial nerve palsy
(n ¼ 2), ischemic stroke (n ¼ 1), primary central
nervous system vasculitis (n ¼ 1), paraneoplastic
encephalitis (n ¼ 1), intoxication due to administered
therapy drugs (n ¼ 2), adenoma hypophysis (n ¼ 1),
and metastases (brain [n ¼ 3], dural [n ¼ 2], and other
locations [n ¼ 3]). FCI was negative for malignancy in
25 cases. In the remaining patient, clinicians excluded
the diagnosis of LC despite positive FCI findings.
This CSF sample had a low volume (1.5 mL) and a low
cell count (,1 cell/mm3). CSF cell populations showed
25% lymphocytes, 53%monocytes, and 8% diploid epi-
thelial cells. This patient received a diagnosis of an undif-
ferentiated tumor of the cavum and was studied for
abrupt dementia. CSF cytology,MRI, and CSF biochem-
istry did not support malignancy. The patient diedwithin
a few days with a medical diagnosis of multifactorial
dementia. A necropsy study was not performed.
Finally, the remaining 3 patients in our series had a
very high clinical suspicion of LC, but MRI and repeated
CSF studies were normal. FCI results were also negative
for malignancy. Likewise, necropsy studies were not per-
formed. In this context, a certain diagnosis of LCwas not
established; thus, these 3 patients were excluded from the
analyses. Table 2 summarizes the relationship between
CSF cytology, FCI findings, and final medical diagnoses.
Sensitivity, specificity, and the positive and negative
predictive values were calculated for every technique
(Table 3). Correlation between cytology and FCI
results was high (k¼ 0.83; 95% CI, 0.70–0.96), but
the rate of misdiagnosis of LC was 35% using only
CSF cytology and 25% using both CSF cytology and
FCI examination (P ¼ .06).
Comparison of FCI Findings Among Patient Groups
Following established medical diagnosis, FCI data were
classified as with or without cytology agreement.
Cytology agreement included true-positive samples for
malignancy (TP; n ¼ 32), true-negative samples (TN;
n ¼ 25), and false-negative samples (FN; n ¼ 12).
Cases with discrepancies between the techniques
included FN cytology but TP FCI (n ¼ 5) and TN
cytology but false-positive (FP) FCI (n ¼ 1). The main
CSF data of the 4 major groups are described in Table 4.
Age, sex, and localization of the primary tumor
showed no differences among groups. Median CSF
sample volume was similar in each group, although
median CSF value of cells/mm3 was higher in the TP
group with regard to the other groups (P, .01). In the
same way, a low cell count (≤1 cell/mm3) was found
in 1 (3%) of 32 patients in the TP Group compared
with 9 (36%) of 25 in the TN group (P, .01) and 4
(33%) of 12 in the FN group (P, .01). Of importance,
the 3 patients in the TN group with ≥50 cells/mm3 had
either infectious (n ¼ 2) or lymphomatous meningitis
(n ¼ 1).
As expected, the median rate of epithelial cells
showed differences between the 2 groups with epithelial
cells in the CSF and the 2 groups without epithelial cells
(based on either positive cytology and FCI or only posi-
tive FCI; P, .001). The median number of epithelial
cells showed no differences among TN, FN, and TP
FCI groups.
The distribution of the different inflammatory cell
compartments was studied (Table 4) to determine
whether any other parameter not related to the detection
of epithelial cells in the CSF could be useful to suspect LC
in the FN group. No differences among groups could be
attributed to the rate of polimorphonuclear cells in the
CSF, but the rate of lymphocytes had a tendency of
increasing in patients without LC. Conversely, mono-
cytes tended to increase in patients with LC, reaching
values .30% in 8 of the 12 patients in the FN group.
This association was observed after comparison of the
TN group with the TP and FN groups (P, .01).
Moreover, the TN and TP FCI groups only showed stat-
istical differences in the distribution of the monocyte
population (P, .01). This correlation did not change
after excluding those CSF with blood contamination
from the analyses (n ¼ 10). An 84% sensitivity and
50% specificity for LC was described for a rate of
Table 2. CSF cytology and FCI findings in the 3 diagnostic
groups
Final diagnosis
LC Not-LC Indeterminate
Pos Cyt/Pos FCI 32 0 0
Neg Cyt/Neg FCI 12 25 3
Neg Cyt/Pos FCI 5 1 0
TOTAL 49 26 3
Abbreviations: LC, leptomeningeal carcinomatosis. Cyt, cytology;
FCI, flow cytometry immunophenotyping.
Table 3. Sensitivity, specificity, PPV and NPV for CSF cytology and FCI evaluation
Sensitivity Specificity PPV NPV
Cytology 65.3 (52.0–78.6) 100 (100–100) 100 (100–100) 60.5 (45.8–75.1)
FCI 75.5 (63.5–87.6) 96.1 (88.8–100) 97.4 (92.3–100) 67.6 (52.5–82.7)
Abbreviations: PPV, positive predictive value; NPV, negative predictive value. FCI, flow cytometry immunophenotyping.
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17.5% of monocytes in the CSF, but according to ROC
curves, an exact cutoff point with enough sensitivity
and specificity to discriminate between positive and nega-
tive cases was not found (Figure 4).
Evaluation of DNA Ploidy
The DNA index could be accurately calculated in 25
patients: 24 were included in the TP group and showed
a hyperdiploid DNA content (DNA index ranging
from 1.6 to 4.24). The remaining patient was included
in the FP FCI group and had a diploid DNA content
(DNA index ¼ 1.02). In the remaining patients in the
TP and TP FCI groups, epithelial cells also had a
higher DNA content compared with lymphocytes
DNA content. However, the scarce number of cells
was not enough to calculate the mathematical value
for a DNA index.
Discussion
Cytology examination of the CSF remains as the
gold standard for LC diagnosis. It identifies LC in
5%–10% of patients with solid tumors, but this inci-
dence might be higher because all series with LC
include patients who received a diagnosis only by
MRI,1,3,20 and necropsy studies reveal LC in 19% of
the evaluated cases.21 Continuous testing of new bio-
markers22,23 indicates the strong necessity of improving
diagnosis of LC. In this work, we introduce a novel FCI
approach to look for malignant epithelial cells in the
CSF based on the identification of the epithelial cell
Fig. 4. ROC analyses for the different percentage of lymphocytes (A) and monocytes (B) described in all cases included in the study.
Table 4. Statistical study of the 4 major groups identified by FCI. %: median percentage of CSF cells. Interquartile range is specified
inside brackets
CSF data TP (n5 32) TN (n5 25) FN (n5 12) TP FCI (n5 5)
Volume 2.7 (2.1–3.5) 2.6 (2.1–3.3) 2.4 (1.4–3.2) 2.3 (2.1–2.7)
Cells/mm3 8.0 (4.8–40.8)a 1.0 (,1–7.0) 1.0 (,1–4.7) ,1
% epithelial cells 14 (3.0–26.5)b 0 0 3.0 (1.5–8.5)c
Epithelial cells/mm3 ,1 (,1–3.75)b ,1 ,1 ,1 (,1–3.0)
% lymphocytes 55 (40–73)d 73 (41–87)e 49 (19–62) 40 (30–65)
% monocytes 35 (19–49) 17 (9–31)f 39 (18–57) 48 (28–68)
% PMN 4 (1–13) 0 (0–15) 2 (0–23) 6 (0–13)
Abbreviations: TP, true positive for malignancy cytology concordant; TN, true negative for malignancy cytology concordant; FN, false negative
cytology/FCI; TP FCI, false negative cytology/true positive FCI; PMN, polimorphonuclear; FCI, flow cytometry immunophenotyping.
aP, .01 vs TN, FN and TP FCI groups.
bP, .001 vs TN and FN groups.
cP ≤ .001 vs TN and FN groups.
dP, .05 vs TN group.
eP, .01 vs FN group.
fP, .01 vs TP, FN, and TP FCI groups.
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adhesion molecule, EpCAM, and description of their
DNA content.
Overall, the results showed a good correlation
between cytology and FCI CSF findings: FCI did not
detect malignant epithelial cells in 25 of 26 patients
for whom the diagnosis of LC was excluded, and all
patients who received a diagnosis of LC according to
CSF cytology also had a positive detection of malignant
cells using FCI. Furthermore, FCI was also able to detect
malignant cells in the CSF of 6 patients with LC and
negative CSF cytology, and in 5 (83%) of them, a
strong diagnosis of LC was established. Of note, com-
parison of both techniques might be biased because of
the number of cytologists participating in the study
and because the CSF volume analyzed was ,10.5 mL,
as recommended for obtaining the highest cytology sen-
sitivity.6 However, our results show that FCI improves
the sensitivity and negative predictive value of classical
CSF cytology, even with the CSF volume obtained and
studying only one CSF sample per patient.24
The key issue of the protocol thatwe propose here is the
identification of EpCAM-positive cells in the CSF.
EpCAM is a cell surface protein expressed on healthy
human epithelia and corresponding malignant
tumors.25–29 Immunohistochemical staining protocols
have shown that most adenocarcinomas express
EpCAM, with differences in intensity of expression
among histology subtypes.25,26,28,29 In general, colon,
ovarian, stomach, pancreas, lung, and breast show high
EpCAM expression (.90%). A much lower expression
(,20%) is exhibited on hepatocellular and clear cell
kidney carcinoma, but our study does not include any of
these. According to some reports,28–30 EpCAM
expression on metastatic cancers may be close to 100%.
From a technical point of view, EpCAM does not need
cell permeabilization (and subsequent loss of cells)
required for identification of cytoplasmic cytokeratin.
EpCAM-positive cells canonly be detected at very low fre-
quencies circulating in peripheral blood;31,32 thus, in con-
trast to leukemia and lymphoma, they cannot interfere
with the analysis of CSF samples contaminated with
blood.13 On the other hand, focusing on the detection of
epithelial cells means that the protocol will not be useful
for detecting LC in patients with melanoma, sarcoma, or
mesothelioma.24–26 Moreover, CSF samples where
meningeal carcinomatosis was excluded and a very high
number of lymphocytes were found should be carefully
evaluated with a larger panel of reagents to exclude the
malignant origin of the lymphoid compartment.
The design of this new FCI protocol, which uses 2
different mAb against different epitopes of the same
molecule EpCAM, intended to solve the following
issues. First, there was a need to recognize a criteria
that helped to cluster the CSF malignant epithelial
cells, because in contrast to most of lymphomas, they
have a very disperse distribution in the forward and
side scatter dot-plot. This probably reflects different
size and granular cell content26,33,34 but makes it very
difficult for FCI to localize them through their physical
properties. Second, there was a need to increase the
chances of detecting low intensity of EpCAM
expression, as described for some histological subtypes
of breast and lung cancers,26,27 because this might
limit the accuracy of FCI. Third, there was a need to
detect low numbers of malignant cells in the CSF
because, in line with the observations by Strik et al;3
.50% of patients in our TP group had either ,5% of
CSF malignant cells or ,1 malignant cell/mm3. The
alignment of EpCAM positive cells showed a homo-
geneous image that helped distinguish epithelial cells
from all the remaining acquired events. Finally, DNA
content has also been useful to identify neoplastic epi-
thelial cells, because all our patients with LC had a
hyperdiploid population. Difficulties may arise when a
diploid cell population is found, as happened in the
only case classified as FP FCI result. In this patient, clini-
cal and laboratory information did not support LC, but
we lacked definitive information from a necropsy.
Tumors in situ may have a diploid content;35 thus,
despite our results, we still believe that LC diagnosis
should not be rejected in diploid cases.
Even with FCI, 24% of patients in our series received
a diagnosis of LC with use of techniques not related to
the identification of pathological cells in the CSF. It
might be a point of argument whether LC should only
be established on clinical and biochemical CSF data,
but most of the patients in our study had positive MRI
findings. Different tumors were involved, but in all
these cases, a very low CSF cell count was found.
Whether this describes a low tumor burden or dimin-
ished free-floating neoplastic CSF cells with lower capa-
bility to metastatize along neuraxis and better survival
prognosis remains to be established. In any case,
because FCI and cytology analyze cells, some of the
reasons described in the literature for explaining FN
cytology could also explain FN FCI results.1,3 A CSF
sample obtained far away from localized meningeal
lesions, CSF flow obstruction, random shedding of
malignant cells, or a diffuse distribution of LC might
justify the absence of malignant cells in the CSF. The
hypothesis of adherent types of LC might also be
suggested,1 and strictly speaking, in all these situations,
FCI and cytology findings should not be considered as
FN results. In these cases with minimal or absent CSF
involvement, searching for epithelial cells in the CSF
would be ineffective for diagnosing LC, but according
to our data, evaluation of the distribution of the inflam-
matory cell compartment might be helpful. When com-
pared with the distribution described in normal CSF,36
monocytes tended to increase in the CSF of patients
with LC in which no epithelial cells were detected. In
contrast, TNCSF samples did not show this distribution,
and lymphocytes were the subpopulation with a major
increase. Little is known about the distribution of the
inflammatory compartment of the CSF in patients with
LC; thus, further studies are needed to determine
which subpopulations of monocytes and lymphocytes
are involved.
In summary, FCI seems to be a promising new tool for
improving the diagnosis of LC in patients with adeno-
carcinoma. As a complement of cytology, FCI might
be particularly useful to identify difficult LC cases with
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a very low rate of malignant cells in the CSF. Studies
with many more patients are needed to determine
whether inclusion of FCI to CSF study would increase
accuracy of standard LC diagnostic tools.
Supplementary Material
Supplementary material is available online at Neuro-
Oncology (http://neuro-oncology.oxfordjournals.org/).
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